ARRY Financial Facts
Total operating expenses: 63.27MResearch and development for proprietary programs: 46.56M
See Full Income Statement
Cash and cash equivalents: 65.84M
Total long-term liabilities: 154.77M
See Full Balance Sheet
Array BioPharma, Inc. (ARRY) Earnings
|
Expand Research on ARRY
| Next EPS Date | 8/11/26 | EPS Growth Rate | -48.0% |
|---|---|---|---|
| Average EPS % Beat Rate | +77.4% | Revenue Growth Rate | -10.7% |
| Average % Move 1-Wk after EPS | -5.1% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/11/26  |
Q226 | N/A | $0.13 | N/A | N/A | $323.62M | = | N/A | N/A | ||
| 5/6/26 | Q126 | $0.06 | -$0.05 | +$0.11 | $223.4M | $210.34M | = |  | | Details | |
| 2/25/26 | Q425 | -$0.01 | $0.00 | -$0.01 | $226M | $212.19M | = | | | Details | |
| 11/5/25 | Q325 | $0.30 | $0.19 | +$0.11 | $393.49M | $305.93M | = | | | Details | |
| 8/7/25 | Q225 | $0.25 | $0.19 | +$0.06 | $362.2M | $291.41M | = | | | Details | |
| 5/6/25 | Q125 | $0.13 | $0.07 | +$0.06 | $302.4M | $256.58M | = | | | Details | |
| 2/27/25 | Q424 | $0.16 | $0.18 | -$0.02 | $275.23M | $272.51M | = | | | Details | |
| 11/7/24 | Q324 | $0.17 | $0.13 | +$0.04 | $231.41M | $232.69M | = | | | Details |
